Selskabets formål er i ind- og udland at drive fabrikation og handel dels direkte, dels ved anbringelse af kapital i andre foretagender. Selskabet kan i øvrigt foretage investeringer i fast ejendom, drive finansieringsvirksomhed samt udøve enhver efter bestyrelsens skøn i forbindelse med formålet stående virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 6.3 mia. | 1.2 mia. | 9.1 mia. | 6.4 mia. | 2737 | |
CVR: 63717916
Secondary names: ALLERGOLOGISK LABORATORIUM A/S, ALK A/S, DIAGNOSELABORATORIET AF 1977 A/S
Previous names: ALLERGOLOGISK LABORATORIUM A/S, ALK A/S
2 properties
Upgrade to Pro to see addresses, building data and ownership details
Companies in the same industry and area
CVR 29526346
CVR 37728403
CVR 40279865
CVR 34623562
CVR 38445928
Compared to 131 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
The financial health of ALK-ABELLÓ A/S appears stable, with a strong equity position of 6.17 billion DKK in 2025, indicating solid capitalization. Revenue has shown a slight decline from 5.54 billion DKK in 2024 to 1.53 billion DKK in 2025, while profit decreased from 815 million DKK to 314 million DKK in the same period, suggesting potential challenges in maintaining profitability. Despite these fluctuations, the company maintains a robust equity base, which is a key strength, although the declining revenue and profit margins raise concerns about future growth. Positioned within the pharmaceutical manufacturing industry, ALK-ABELLÓ A/S is a significant player, but it will need to address these trends to sustain its competitive edge.
AI-generated summary
Henriette Mersebach left as director
Christina Malling joined the board
Anders Nørgaard joined the board
Morten Lüthje left the board
Jakob Simonsen left the board
Søren Daniel Niegel left as director
companydata.dk